Why do big pharmaceutical companies subcontract other companies to manufacture active pharmaceutical ingredients?

Big pharmaceutical companies subcontract the manufacturing of active pharmaceutical ingredients (APIs) to specialized companies to reduce costs, enhance efficiency, and streamline operations. Outsourcing allows them to leverage the expertise and advanced technologies of contract manufacturers, which can often produce high-quality APIs at lower costs. This strategy also enables pharmaceutical companies to focus on their core competencies, such as research and development, while ensuring compliance with regulatory standards. Additionally, subcontracting can provide greater flexibility in scaling production to meet fluctuating market demands.